Knowledge and Awareness of Dentists Working At a Denta L Hospita L In a City About Bone Osteonecrosis Due To Medicat Ion
Abstract
Purpose: This study aimed to evaluate the knowledge and awareness of dentists working at a Dental Hospital about bone osteonecrosis in jaws depending on related to the drugs and mechanisms of action of antiresorptive drugs. Patients and Methods: This study was completed by evaluating a total of 35 16 female and 19 male dentists aged between 26 and 55 who worked at a Dental Hospital in a city. Participants were asked to complete a questionnaire including questions on socio-demographic and antiresorptive medications, osteonecrosis of the bone, and treatment n=35 . According to the answers given to the questions; the levels of awareness and information ownership were evaluated. Results: The bone osteonecrosis related to pharmacology and treatmentin addition to the rate of knowledge and awareness of antiresorptive drugs were found as 42.9%. Of the total 35 dentists, 15 responded yes to 60% of the questionnaire and provided necessary explanations. No statistically significant difference was found between the number of male and female dentists who actively participated in congresses related to dentistry and regularly followed related journals, had experience in a private sector, had knowledge and awareness about both bone osteonecrosis due to pharmacy and treatment and antiresorptive drugs p>0,05 . Conclusion: It was understood that the dentists who worked at a Dental Hospital had a low level of knowledge and awareness about antiresorptive drugs and their mechanisms of action, jaw osteonecrosis caused by these drugs and the treatments. There is a need for more extensive and broader research
References
- Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT. A systematic review of bisphosphonate osteonecrosis (bon) in cancer. Support Care Cancer 2010;18:1099–106. [CrossRef]
- Soydan SS, Veziroğlu Şenel F, Araz K. Bifosfonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteonekrozun Patogenezi ve Tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi 2009;33:61– 8. Erişim: http://www.dishekdergi.hacettepe.edu.tr/htdergi/ makaleler/2009sayi3makale8.pdf
- Ruggiero S, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw. Aust Endod J 2009;35:119–30. [CrossRef]
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial MRONJ derleme Tayfun Yazıcı ve ark. Surgeons on Medication-Related Osteonecrosis of the Jaw— 2014 Update. J Oral Maxillofac Surg 2014;72:1938–56. [CrossRef]
- Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014;53:19–31. [CrossRef]
- Rizzoli R. Bisphosphonates for postmenopausal osteoporosis: Are they all the same? QJM 2011;104:281–300. [CrossRef]
- Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753–61. [CrossRef]
- Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Radiol Endod 2010;110:46–53. [CrossRef]
- Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K, et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 2013;5:5. [CrossRef]
- Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–36. [CrossRef]
- King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28:667–77. [CrossRef]
- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75. [CrossRef]
- Soğur E, Önem E, Baksı BG. Bisfosfanat kullanımına bağlı çene kemiğinde gelişen osteonekroz: Etyoloji, risk faktörleri, tanı kriterleri ve tedavi alternatifleri. Atatürk Üniv Diş Hek Fak Derg 2012;22:83–95.
- Eke HN. An Empirical Study of the Impact of NLA Conference Attendance on Librarians’ Professional Development. PNLA Quarterly 2011;75:26–37.
- Zineldin M. The Quality of Health Care And Patient Satisfaction: an Exploratory Investigation of the 5Qs Model at Some Egyptian and Jordanian Medical Clinics. Int J Health Care Qual Assur Inc Leadersh Health Serv 2006;19:60–92. [CrossRef]
Bir İlde Ağız ve Diş Sağlığı Merkezinde Çalışan Diş Hekimlerinin İlaca Bağlı Oluşan Kemik Osteonekrozu Hakkında Bilgi ve Farkındalıkları
Abstract
Amaç: Ağız ve Diş Sağlığı Merkezi’nde çalışan hekimlerin antirezorptif ilaçlar ve etki mekanizmaları, ilaca bağlı olarak çenelerde oluşan kemik osteonekrozu hakkında bilgi ve farkındalıklarının değerlendirilmesi amaçlanmıştır. Hastalar ve Yöntemler: Bu çalışma, bir ilde bulunan Ağız ve Diş Sağlığı Merkezi’nde çalışan yaşları 26-55 arasında olan toplam 35 16 kadın ve 19 erkek diş hekiminin değerlendirilmesiyle gerçekleştirildi. Katılımcılardan; sosyo-demografik ve antiresorptif ilaçlar, ilaca bağlı oluşan kemik osteonekrozu ve tedavisi konularında sorular içeren anketi doldurmaları istendi n=35 . Sorulara verilen cevaplara göre farkındalık ve bilgi sahipliği düzeyleri değerlendirildi. Bulgular: İlaca bağlı oluşan kemik osteonekrozu ve tedavisi, antiresorptif ilaçlar hakkında bilgi ve farkındalık oranı ise %42,9 olarak bulunmuştur. Toplam 35 hekimin 15 tanesi anket sorularının %60’ına evet cevabı vererek, gerekli açıklamalarda bulunmuşlardır. Diş hekimliği ile ilgili kongrelere aktif olarak katılan ve ilgili dergileri düzenli takip eden ve özel sektörde iş tecrübesi olan, ilaca bağlı oluşan kemik osteonekrozu ve tedavisi, antiresorptif ilaçlar hakkında bilgi ve farkındalığa sahip olan kadın ve erkek hekim sayısı arasında istatistiksel olarak anlamlı bir fark bulunmamıştır p>0,05 . Sonuç: Ağız ve Diş Sağlığı Merkezi’nde çalışan diş hekimlerinin antiresorptif ilaçlar ve etki mekanizmaları, bu ilaçların neden oldukları çene osteonekrozları ve tedavileri hakkında bilgi ve farkındalık seviyelerinin düşük olduğu ortaya koyulmuştur. Daha kapsamlı ve daha geniş kitleleri içine alacak çalışmalara ihtiyaç duyulmaktadır
References
- Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT. A systematic review of bisphosphonate osteonecrosis (bon) in cancer. Support Care Cancer 2010;18:1099–106. [CrossRef]
- Soydan SS, Veziroğlu Şenel F, Araz K. Bifosfonata Bağlı Olarak Çene Kemiklerinde Gelişen Osteonekrozun Patogenezi ve Tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi 2009;33:61– 8. Erişim: http://www.dishekdergi.hacettepe.edu.tr/htdergi/ makaleler/2009sayi3makale8.pdf
- Ruggiero S, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw. Aust Endod J 2009;35:119–30. [CrossRef]
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial MRONJ derleme Tayfun Yazıcı ve ark. Surgeons on Medication-Related Osteonecrosis of the Jaw— 2014 Update. J Oral Maxillofac Surg 2014;72:1938–56. [CrossRef]
- Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014;53:19–31. [CrossRef]
- Rizzoli R. Bisphosphonates for postmenopausal osteoporosis: Are they all the same? QJM 2011;104:281–300. [CrossRef]
- Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753–61. [CrossRef]
- Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Radiol Endod 2010;110:46–53. [CrossRef]
- Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K, et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 2013;5:5. [CrossRef]
- Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–36. [CrossRef]
- King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28:667–77. [CrossRef]
- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75. [CrossRef]
- Soğur E, Önem E, Baksı BG. Bisfosfanat kullanımına bağlı çene kemiğinde gelişen osteonekroz: Etyoloji, risk faktörleri, tanı kriterleri ve tedavi alternatifleri. Atatürk Üniv Diş Hek Fak Derg 2012;22:83–95.
- Eke HN. An Empirical Study of the Impact of NLA Conference Attendance on Librarians’ Professional Development. PNLA Quarterly 2011;75:26–37.
- Zineldin M. The Quality of Health Care And Patient Satisfaction: an Exploratory Investigation of the 5Qs Model at Some Egyptian and Jordanian Medical Clinics. Int J Health Care Qual Assur Inc Leadersh Health Serv 2006;19:60–92. [CrossRef]
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Research Article |
| Authors | |
| Publication Date | September 1, 2019 |
| Published in Issue | Year 2019Issue: 3 |